HR6897

The Thyroid Disease CARE Act of 2025, HR6897, authorizes $30,000,000 annually for fiscal years 2026 through 2030 for thyroid disease research and related activities. This funding targets investigating root causes, improving diagnostic techniques, developing treatments, enhancing thyroid cancer care, and assessing disparities. This represents a direct injection of $150 million over five years into the healthcare research ecosystem specifically for thyroid conditions. The money trail for this legislation flows directly to research institutions and companies capable of conducting advanced medical research, developing diagnostic tools, and innovating treatments. The Secretary, in consultation with the National Academies of Sciences, Engineering, and Medicine, will conduct or support this research. This mechanism typically involves grants and contracts awarded to academic institutions, biotechnology firms, and medical device manufacturers. Companies specializing in diagnostic testing for thyroid function and cancer, as well as those developing new therapeutic agents, are positioned to benefit from increased research funding and improved diagnostic techniques. Historically, increased federal funding for specific disease research has driven innovation and market growth for relevant companies. For example, the 21st Century Cures Act, signed into law in December 2016, provided significant funding for medical research. Following its passage, companies involved in drug discovery and medical technology saw sustained growth. While not directly comparable in scale, targeted research funding consistently stimulates activity in the relevant sectors. The bill's sponsorship by Rep. Stevens (D-MI-11), a member of the majority party, and its referral to the Energy and Commerce Committee, a key committee for health legislation, indicates a standard legislative process. Specific winners include companies involved in diagnostic testing and research tools. Abbott Laboratories ($ABT) manufactures thyroid function tests. Quest Diagnostics ($DGX) and LabCorp ($LH) provide extensive thyroid testing services. Thermo Fisher Scientific ($TMO) and Illumina ($ILMN) supply research equipment and genetic sequencing technologies crucial for understanding disease causes and developing advanced diagnostics. Hologic ($HOLX) develops diagnostic and surgical products that could benefit from improved thyroid cancer care. There are no direct losers identified by this bill; rather, it creates opportunities for growth within the thyroid disease research and treatment space. Next, the bill will undergo consideration by the House Committee on Energy and Commerce. If approved, it will proceed to a House vote. If passed by the House, it moves to the Senate for consideration. The authorization of appropriations for fiscal years 2026 through 2030 means that if enacted, funding would become available starting October 1, 2025, for the 2026 fiscal year.